{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:04:42Z","timestamp":1776783882677,"version":"3.51.2"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    Primary cutaneous diffuse large B-cell lymphoma\u2013leg type (PCDLBCL-LT) is a rare and aggressive lymphoma of elderly patients, typically affecting the lower extremities and characterized by centroblast- and immunoblast-like cells with a non-germinal center phenotype (MUM1+, BCL2+, IgM+, CD10-). CD5-positive cases are exceptionally uncommon and pose a diagnostic challenge, as CD5 expression broadens the differential diagnosis to include other B-cell lymphomas such as mantle cell lymphoma and transformed chronic lymphocytic leukemia. We describe a 70-year-old female patient who presented with a 2-cm cutaneous nodule on the lower extremity. Histopathology revealed a pandermal diffuse infiltrate of atypical large B-cells. Immunohistochemistry showed a CD5+, CD20+, MUM1+, BCL2+, IgM+, cyclin D1-profile, supporting CD5\n                    <jats:sup>+<\/jats:sup>\n                    PCDLBCL-LT. Fluorescence in situ hybridization for\n                    <jats:italic toggle=\"yes\">MYC<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">BCL2<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">BCL6<\/jats:italic>\n                    rearrangements were negative, effectively ruling out double-hit\/triple-hit lymphoma. The patient achieved a complete metabolic response after six cycles of R-CHOP chemotherapy, which was maintained for 24 months. However, she subsequently developed extracutaneous relapse involving the soft tissues of the extremities, trunk, and periorbital region, consistent with a progression. Treatment with a rituximab\u2013bevacizumab combination regimen induced a second complete remission, sustained for six months at the time of reporting. Our case highlights the importance of routine CD5 testing in PCDLBCL-LT to identify this distinct subgroup and to guide appropriate differential diagnosis and patient monitoring.\n                  <\/jats:p>","DOI":"10.1097\/dad.0000000000003258","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:00:20Z","timestamp":1772647220000},"page":"370-373","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: An Unusual Presentation"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3057-0319","authenticated-orcid":false,"given":"Anna A.","family":"Kozyreva","sequence":"first","affiliation":[{"name":"UNIM LLC, Moscow, Russia; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2512-1951","authenticated-orcid":false,"given":"Ilya V.","family":"Tsvetnov","sequence":"additional","affiliation":[{"name":"UNIM LLC, Moscow, Russia; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9983-9735","authenticated-orcid":false,"given":"Kirill A.","family":"Lyapichev","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, Cleveland Clinic Florida, Weston, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2313-1489","authenticated-orcid":false,"given":"Ihar I.","family":"Haiduk","sequence":"additional","affiliation":[{"name":"UNIM LLC, Moscow, Russia; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"R1-20260421","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"R2-20260421","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"R4-20260421","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ajh.26968","article-title":"Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov","year":"2023","journal-title":"Am J Hematol."},{"key":"R6-20260421","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases","volume":"143","author":"Grange","year":"2007","journal-title":"Arch Dermatol."},{"key":"R7-20260421","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/DAD.0b013e3181eeb433","article-title":"The histomorphologic spectrum of primary cutaneous diffuse large B-cell lymphoma: a study of 79 cases","volume":"33","author":"Plaza","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00428-022-03421-5","article-title":"Recent advances in cutaneous lymphoma-implications for current and future classifications","volume":"482","author":"Goodlad","year":"2023","journal-title":"Virchows Arch."},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/PAS.0b013e3181e5060a","article-title":"IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma","volume":"34","author":"Koens","year":"2010","journal-title":"Am J Surg Pathol."},{"key":"R10-20260421","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.leukres.2011.06.004","article-title":"The expression of IgM is helpful in the differentiation of primary cutaneous diffuse large B cell lymphoma and follicle center lymphoma","volume":"35","author":"Demirkesen","year":"2011","journal-title":"Leuk Res."},{"key":"R11-20260421","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.18632\/oncotarget.3479","article-title":"Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries","volume":"6","author":"Xu-Monette","year":"2015","journal-title":"Oncotarget"},{"key":"R12-20260421","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41423-020-0490-z","article-title":"CD5 and B lymphocyte responses: multifaceted effects through multitudes of pathways and channels","volume":"17","author":"Taher","year":"2020","journal-title":"Cell Mol Immunol."},{"key":"R13-20260421","doi-asserted-by":"crossref","first-page":"941347","DOI":"10.3389\/fonc.2022.941347","article-title":"Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol."},{"key":"R14-20260421","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jid.2022.07.027","article-title":"Disease-defining molecular features of primary cutaneous B-cell lymphomas: implications for classification and treatment","volume":"143","author":"Zhang","year":"2023","journal-title":"J Invest Dermatol."},{"key":"R15-20260421","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40257-022-00704-0","article-title":"Update in diagnosis and management of primary cutaneous B-cell lymphomas","volume":"23","author":"Krenitsky","year":"2022","journal-title":"Am J Clin Dermatol."},{"key":"R16-20260421","doi-asserted-by":"crossref","first-page":"104109","DOI":"10.1016\/j.lpm.2022.104109","article-title":"Cutaneous B-cell lymphomas: update on diagnosis, risk-stratification, and management","volume":"51","author":"Fava","year":"2022","journal-title":"Presse Med."},{"key":"R17-20260421","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.1996.5421085.x","article-title":"Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome","volume":"93","author":"Zoldan","year":"1996","journal-title":"Br J Haematol."},{"key":"R18-20260421","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"key":"R19-20260421","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1007\/s00277-024-05974-8","article-title":"Recent advances in CD5(+) diffuse large B-cell lymphoma","volume":"103","author":"Yue","year":"2024","journal-title":"Ann Hematol."},{"key":"R20-20260421","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med."},{"key":"R21-20260421","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1182\/bloodadvances.2023010757","article-title":"Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma","volume":"7","author":"Gerson","year":"2023","journal-title":"Blood Adv."},{"key":"R22-20260421","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3324\/haematol.12810","article-title":"De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients","volume":"93","author":"Yamaguchi","year":"2008","journal-title":"Haematologica"},{"key":"R23-20260421","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1080\/10428194.2021.1953010","article-title":"CD5+ diffuse large B-cell lymphoma: a narrative review","volume":"62","author":"Durani","year":"2021","journal-title":"Leuk Lymphoma."},{"key":"R24-20260421","doi-asserted-by":"crossref","first-page":"e70047","DOI":"10.1002\/hon.70047","article-title":"Treatments and outcomes of newly diagnosed CD5-positive diffuse large B-cell lymphoma: a multi-institutional observational study","volume":"43","author":"Nato","year":"2025","journal-title":"Hematol Oncol."},{"key":"R25-20260421","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jid.2018.04.038","article-title":"Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type","volume":"138","author":"Zhou","year":"2018","journal-title":"J Invest Dermatol."},{"key":"R26-20260421","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/modpathol.2013.156","article-title":"Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma","volume":"27","author":"Pham-Ledard","year":"2014","journal-title":"Mod Pathol."},{"key":"R27-20260421","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","article-title":"Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing","volume":"137","author":"Mareschal","year":"2017","journal-title":"J Invest Dermatol."},{"key":"R28-20260421","doi-asserted-by":"crossref","first-page":"20406207211072839","DOI":"10.1177\/20406207211072839","article-title":"MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy","volume":"13","author":"Chen","year":"2022","journal-title":"Ther Adv Hematol."},{"key":"R29-20260421","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/annonc\/mdn666","article-title":"Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma","volume":"20","author":"Ruan","year":"2009","journal-title":"Ann Oncol."},{"key":"R30-20260421","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.3390\/ijms20194740","article-title":"The CXCR4-CXCL12-axis is of prognostic relevance in DLBCL and its antagonists exert pro-apoptotic effects in vitro","volume":"20","author":"Pansy","year":"2019","journal-title":"Int J Mol Sci."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:01:05Z","timestamp":1776780065000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003258","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}